# Enhertu是由第一三共（Daiichi Sankyo，DSNKY）發現，並由阿斯利康（AstraZeneca，AZN）共同開發及商業化的專門設計針對HER2的DXd抗體藥物偶聯物

*biotech · news · 2026-05-15 · Markets Insider*

## Key points

- FDA核准Enhertu用於HER2陽性第2或第3期乳癌的新輔助治療。
- Enhertu現已獲准用於HER2陽性患者有殘留侵襲性疾病的輔助治療階段。
- 這是Enhertu首次獲FDA核准用於早期HER2陽性乳癌治療。
- Enhertu由第一三共與阿斯利康共同開發及商業化。

Enhertu has been approved by the U.S. FDA for two new breast cancer indications in the neoadjuvant and adjuvant settings of patients with HER2 positive early breast cancer. In the neoadjuvant setting, Enhertu followed by a taxane, trastuzumab and pertuzumab has been approved for the treatment of adult patients with HER2 positive stage 2 or stage 3 breast cancer. In the adjuvant setting, Enhertu has been approved for the treatment of adult patients with HER2 positive breast cancer who have residual invasive disease following neoadjuvant trastuzumab and taxane-based treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate discovered by Daiichi Sankyo (DSNKY) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (AZN). Claim 55% Off TipRanks

**Companies:** AstraZeneca, Daiichi Sankyo
**Countries:** United States

[Read the full story on Markets Insider](https://markets.businessinsider.com/news/stocks/fda-approves-enhertu-for-two-new-breast-cancer-indications-1036166013)

---

Canonical: https://newsio.io/zh-TW/n/e9c7ef2b-4388-485a-95c1-6101ca6b2e57/enhertudaiichi-sankyodsnkyastrazenecaaznher2dxd
Summarized by Newsio from Markets Insider. https://newsio.io/how-it-works